Biotechnology

Revitope And Junshi Biosciences Enter Into Research Collaboration And License Agreement To Explore Next Generation Immunotherapies With Precision-Targeted T-Cell Engaging Antibodies

- Novel antibody-based cancer immunotherapies to be developed through combining Revitope's dual-antigen precision T-cell engager platform (TEAC) and Junshi Biosciences' antibodies - Revitope to design up to 5 TEAC molecules against tumor targets selected by Junshi Biosciences - For each TEAC mo...

2020-07-14 09:01 6502

Frost & Sullivan Reveals Technological Advances Facilitating Research across Preclinical Disease Models

Five technologies empowering preclinical disease modeling are providing preclinical research with highly accurate and precise services SANTA CLARA, California, July 14, 2020 /PRNewswire/ -- Frost & Sullivan's recent analysis,Technological Advances Facilitating Research across Preclinical Disease...

2020-07-14 01:55 1504

NTHU Research Team Develops a Rapid Test Kit for Potential Severe Covid-19 Cases

HSINCHU, July 13, 2020 /PRNewswire/ -- Professor Cheng Chao-Min of the Institute of Biomedical Engineering at National Tsing Hua University has recently developed a new covid-19 rapid test kit which allows the physician to provide timely treatment to high-risk patients, thereby making more effici...

2020-07-14 01:00 1277

PQE Group Creates an Internal Research Task Force to Fight Fake News in Relation to COVID-19

FLORENCE, Italy, July 13, 2020 /PRNewswire/ -- With the pandemic caused by COVID-19, the continuous need to obtain information has pushed people to rely on unreliable sources, thus fomenting thespread of fake news. For this reason Gilda D'Incerti, CEO and founder of PQE Group

2020-07-13 16:00 2670

Samsung Biologics signs additional development and manufacturing agreement with STCube

SONGDO, South Korea, July 11, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate. STM418 received much attention from the biopha...

2020-07-12 08:00 1786

World's First FDA IDE Coronary Patient Treated With a DEB

NYON, Switzerland, July 11, 2020 /PRNewswire/ --  MedAlliance has announced enrollment of the first patient in its study ofSELUTION SLR™ 014 DEB  for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its 'Breakthrough Progr...

2020-07-11 08:00 3383

Sedana Medical Announces Positive Top Line Result in Pivotal IsoConDa Study

STOCKHOLM, July 10, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a positive top line result for the company's pivotal phase III study, IsoConDa. The study reached its primary endpoint; to show that IsoConDa (isoflurane), administered with AnaConDa, is an ef...

2020-07-10 13:32 1671

PolyU discovers the effect of chemical compound PTU on autophagy in zebrafish embryos, sheds light on cancer medication research

HONG KONG, July 10, 2020 /PRNewswire/ -- The zebrafish has been utilised as a model organism for biomedical research globally for half a century, mainly due to the high genetic similarity (over 70%) between zebrafish and human genes, with over 80% of human morbid genes related to at least one zeb...

2020-07-10 10:18 2801

WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia

SHANGHAI and SAN DIEGO, July 9, 2020 /PRNewswire/ -- WuXi AppTec is pleased to announce that they are about to launch the second session of the webinar series "Collaborations That Transform," highlighting the impact of partnerships in bringing effective therapies to patients. This complimentary w...

2020-07-09 16:32 1600

AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program

SEATTLE, July 9, 2020 /PRNewswire/ -- Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO)AGC Biologics is partnering with clinical-stage biotech companyMolecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®. AGC Biologics...

2020-07-09 13:00 2845

Innovent Announces First Patient Dosed in a Phase 1b Clinical Trial of Sintilimab plus Surufatinib in Advanced Malignancies in China

SUZHOU, China, July 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today anno...

2020-07-09 08:00 12379

Paige Applauded by Frost & Sullivan for its Leading AI-based Computational Pathology Offering that Enables Fast and Accurate Cancer Diagnoses

Paige leveraged the world's largest dataset in pathology to develop an unparalleled computation pathology offering SANTA CLARA, California, July 8, 2020 /PRNewswire/ -- Based on its recent analysis of the North American AI-based digital pathology market, Frost & Sullivan recognizesPaige with the...

2020-07-08 23:40 1781

Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis

STOCKHOLM, July 8, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to c...

2020-07-08 14:57 1803

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China

SHANGHAI, July 8, 2020 /PRNewswire/ -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced an...

2020-07-08 11:37 2843

Evive Biotech meets primary and secondary endpoints in global Phase III clinical trial for their novel chemotherapy-induced neutropenia treatment

* Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF * Key milestone and validation for Evive's novel biologic development capability and technology platform * Key component of the asset's BLA submission to receive re...

2020-07-08 09:00 1903

ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States

DAEJEON, South Korea, July 7, 2020 /PRNewswire/ -- ILIAS Biologics Inc. (the "Company" or "ILIAS"), a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO). A patent...

2020-07-08 01:00 1350

A Breakthrough in Cancer Treatment: Soundny Presents a New Drug-based Alternative in Fight Against Cancer

WUHAN, China, July 7, 2020 /PRNewswire/ -- Hubei Soundny Biotechnology ("Soundny" or the "Company"), a leading biotechnology company dedicated to developing cancer treatments, has published its latest findings on cholangiocarcinoma in Nature Biomedical Engineering, a Nature publication. The rese...

2020-07-07 18:09 1146

Genesis Healthcare Co. launched 'GeneLife Generations', a New Ancestry Kit Designed for the Diversity and Richness of Asian Ethnicities and Ancestral Heritage

SINGAPORE, July 7, 2020 /PRNewswire/ -- Genesis Healthcare Co., Japan's leading genetic testing and research company, today announced the launch of its Asian ancestry focused test kit,GeneLife Generations. The test kit will be officially available to customers from20 July 2020.

2020-07-07 17:32 2717

A Breakthrough in Cancer Treatment: Soundny Presents a New Drug-based Alternative in Fight Against Cancer

WUHAN, China, July 7, 2020 /PRNewswire/ -- Hubei Soundny Biotechnology ("Soundny" or the "Company"), a leading biotechnology company dedicated to developing cancer treatments, has announced the publication of its latest findings on cholangiocarcinoma in Nature Biomedical Engineering, a Nature pu...

2020-07-07 13:25 1089

Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells

HOUSTON, July 7, 2020 /PRNewswire/ -- Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), p...

2020-07-07 11:15 1767
1 ... 284285286287288289290 ... 306